T84.023D

✓ Billable

Instability of internal left knee prosthesis, subsequent encounter

Injury, poisoning and certain other consequences of external causes (S00-T88)

Check This Code

⚠️ Excludes2

inherited

Rules inherited from parent codes.

  • failure and rejection of transplanted organs and tissues (T86.-)
  • fracture of bone following insertion of orthopedic implant, joint prosthesis or bone plate (M96.6)

Clinical Description

ICD-10-CM code T84.023D represents instability of internal left knee prosthesis, subsequent encounter. This code falls under the Injury, poisoning and certain other consequences of external causes (S00-T88) classification. It is a billable/specific code valid for HIPAA-covered transactions as of October 1, 2025 (FY2026). This code can be used to indicate a diagnosis for reimbursement purposes on insurance claims.

This is a 8-character code at the 7th level of specificity. This is the most specific code available in this subcategory.

Frequently Asked Questions

What is ICD-10 code T84.023D?

ICD-10-CM code T84.023D is "Instability of internal left knee prosthesis, subsequent encounter". It belongs to the category: Injury, poisoning and certain other consequences of external causes (S00-T88).

Is T84.023D a billable ICD-10 code?

Yes, T84.023D is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.

Can T84.023D be coded with other codes?

T84.023D has 2 Excludes2 note(s). These conditions can be coded together if both are documented in the patient record.

Related Codes in T84.023

Other codes in the same category that may be relevant for differential coding:

🧪 Validate Combinations

Add T84.023D to the Excludes Checker to validate against your full code list.

Open in Checker →

Code Information

CodeT84.023D
BillableYes
ParentT84.023
CategoryInjury, poisoning and certain other consequences of external causes (S00-T88)
Excludes10 rule(s)
Excludes22 note(s)

Data Source

CMS ICD-10-CM 2026 Tabular List

Updated October 1, 2025 (FY2026)